<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05078541</url>
  </required_header>
  <id_info>
    <org_study_id>CRE-2021.412</org_study_id>
    <nct_id>NCT05078541</nct_id>
  </id_info>
  <brief_title>RFA for Warthin's Tumor</brief_title>
  <official_title>Ultrasound-guided Radiofrequency Ablation of Parotid Warthin's Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is done to compare ultrasound guided radiofrequency ablation of parotid Warthin's&#xD;
      tumor to parotidectomy in terms of tumor size reduction, cosmetic scores, complication rate,&#xD;
      as well as required resources.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiofrequency ablation is minimally invasive and is used in benign disease, including&#xD;
      thyroid nodules, head and neck nodules, and vascular malformations, as well as some malignant&#xD;
      tumors. For patients unable to or unwilling to undergo surgical resection, real-time&#xD;
      ultrasound guided radiofrequency ablation for parotid Warthin's Tumor would be a further&#xD;
      option besides observation alone.&#xD;
&#xD;
      We will recruit 20 patients with Warthin's tumor from the ENT Head and Neck Surgery&#xD;
      out-patient clinic at Prince of Wales Hospital. The patient will first be asked if they&#xD;
      wanted intervention for their condition of Warthin's Tumor. Parotidectomy will first be&#xD;
      offered. If the patient opted for intervention but declines parotidectomy, then ultrasound&#xD;
      guided RFA will be offered.&#xD;
&#xD;
      We will use the 2019 - 2020 Parotidectomy for Warthin's tumor internal audit as a historical&#xD;
      comparison to the ultrasound guided RFA group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual analogue scale for patient satisfaction</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analogue scale for pain</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cosmetic score</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dimensions and volume reduction of Warthin's tumor</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Perioperative complication</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost and resources</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-patient stay</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operating time</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Radiofrequency Ablation</condition>
  <arm_group>
    <arm_group_label>RFA Warthins Tumor Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group of patients who will under RFA for Warthin's tumor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasound-guided Radiofrequency Ablation of Parotid Warthin's Tumor</intervention_name>
    <description>The Procedure&#xD;
Injection of local subcutaneous and pericapsular anaesthesia&#xD;
Needle radiofrequency ablation under ultrasound guidance&#xD;
Patients should communicate with operating surgeon upon excessive heat or pain&#xD;
The procedure usually lasts 30-45 minutes</description>
    <arm_group_label>RFA Warthins Tumor Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years and older&#xD;
&#xD;
          2. Ultrasound scan findings:&#xD;
&#xD;
               1. Tumor size 2cm-5cm&#xD;
&#xD;
               2. Tumor located in superficial lobe of parotid gland with epicenter in Parotid tail&#xD;
&#xD;
          3. Tumor is clinically palpable tumor&#xD;
&#xD;
          4. Symptomatic disease with facial asymmetry and cosmetic concerns&#xD;
&#xD;
          5. Diagnosis confirmed by fine needle aspiration x 2&#xD;
&#xD;
               1. Warthin's tumor&#xD;
&#xD;
               2. No other parotid pathologies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Facial nerve palsy&#xD;
&#xD;
          2. History of parotid surgery&#xD;
&#xD;
          3. History or Symptoms of sialolithiasis&#xD;
&#xD;
          4. Medical facial skin conditions&#xD;
&#xD;
          5. Bleeding tendencies&#xD;
&#xD;
          6. Pregnancy&#xD;
&#xD;
          7. Pacemaker&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 4, 2021</study_first_submitted>
  <study_first_submitted_qc>October 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>David Yeung</investigator_full_name>
    <investigator_title>Resident</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenolymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

